BR112022017305A2 - Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas - Google Patents
Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmasInfo
- Publication number
- BR112022017305A2 BR112022017305A2 BR112022017305A BR112022017305A BR112022017305A2 BR 112022017305 A2 BR112022017305 A2 BR 112022017305A2 BR 112022017305 A BR112022017305 A BR 112022017305A BR 112022017305 A BR112022017305 A BR 112022017305A BR 112022017305 A2 BR112022017305 A2 BR 112022017305A2
- Authority
- BR
- Brazil
- Prior art keywords
- cldn6
- binding molecules
- binding
- specific antigen
- molecules targeting
- Prior art date
Links
- 102000003859 Claudin-6 Human genes 0.000 title abstract 2
- 108090000229 Claudin-6 Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 102100038449 Claudin-6 Human genes 0.000 abstract 6
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 abstract 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
MOLÉCULAS DE LIGAÇÃO AO ANTÍGENOS MULTIESPECÍFICAS QUE TÊM COMO ALVO CLAUDINA-6 E USOS DAS MESMAS. A presente invenção refere-se a moléculas de ligação ao antígeno multiespecíficas capazes de se ligar a CD3 e CD137 (4-1BB), mas não se ligar a CD3 e CD137 ao mesmo tempo e capazes de se ligar a CLDN6. As moléculas de ligação ao antígeno multiespecíficas da presente divulgação exibem atividade de citotoxicidade dependente de células T aumentada de uma maneira dependente de CLDN6 através da ligação a CD3/CD37 e CLDN6. A presente invenção fornece moléculas de ligação ao antígeno multiespecíficas e composições farmacêuticas das mesmas que podem ser utilizadas para ter como alvo células que expressam CLDN6, para uso em imunoterapia para o tratamento de vários cânceres, especialmente aqueles associados à CLDN6, como cânceres CLDN6-positivos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020062881 | 2020-03-31 | ||
| JP2020073335 | 2020-04-16 | ||
| PCT/JP2021/013526 WO2021200939A1 (en) | 2020-03-31 | 2021-03-30 | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017305A2 true BR112022017305A2 (pt) | 2022-10-11 |
Family
ID=77928433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017305A BR112022017305A2 (pt) | 2020-03-31 | 2021-03-30 | Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230220066A1 (pt) |
| EP (1) | EP4126956A4 (pt) |
| JP (2) | JP6971419B2 (pt) |
| KR (2) | KR20220149774A (pt) |
| CN (1) | CN115397855A (pt) |
| AU (1) | AU2021247916A1 (pt) |
| BR (1) | BR112022017305A2 (pt) |
| CA (1) | CA3174094A1 (pt) |
| CL (2) | CL2022002625A1 (pt) |
| CO (1) | CO2022015202A2 (pt) |
| CR (1) | CR20220540A (pt) |
| IL (1) | IL296478A (pt) |
| MX (1) | MX2022012092A (pt) |
| PE (1) | PE20221760A1 (pt) |
| SG (1) | SG11202104264TA (pt) |
| TW (2) | TW202235442A (pt) |
| WO (1) | WO2021200939A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2989110T3 (es) | 2013-11-11 | 2024-11-25 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno que contiene región variable de anticuerpo modificada |
| EP3720963A4 (en) | 2017-12-05 | 2021-12-08 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137 |
| WO2023053282A1 (ja) * | 2021-09-29 | 2023-04-06 | 中外製薬株式会社 | がんの治療に用いるための細胞傷害誘導治療剤 |
| EP4460527A1 (en) * | 2022-01-09 | 2024-11-13 | I-Mab Biopharma Co., Ltd. | Multispecific constructs and uses thereof |
| WO2024085166A1 (ja) * | 2022-10-19 | 2024-04-25 | アステラス製薬株式会社 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
| TW202430574A (zh) | 2022-11-30 | 2024-08-01 | 美商積分分子股份有限公司 | 針對密連蛋白６之抗體，包括其雙特異性格式 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2241578B1 (en) | 2008-01-11 | 2016-04-20 | The University of Tokyo | Anti-cldn6 antibody |
| LT2499161T (lt) | 2009-11-11 | 2017-11-27 | Ganymed Pharmaceuticals Gmbh | Specifiniai antikūnai, skirti klaudinui 6 (cldn6) |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| DK2707390T3 (en) | 2011-05-13 | 2016-02-29 | Ganymed Pharmaceuticals Ag | ANTIBODIES TO TREAT CANCER EXPRESSING CLAUDIN 6 |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| KR102643443B1 (ko) | 2012-11-13 | 2024-03-06 | 비온테크 에스이 | 클라우딘 발현 암 질환의 치료제 |
| CA2928671A1 (en) | 2013-11-06 | 2015-05-14 | Stemcentrx, Inc. | Novel anti-claudin antibodies and methods of use |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| EP3720963A4 (en) * | 2017-12-05 | 2021-12-08 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137 |
| US20210054076A1 (en) * | 2018-01-05 | 2021-02-25 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| WO2020067399A1 (en) * | 2018-09-28 | 2020-04-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region |
| SG11202112307YA (en) * | 2019-07-10 | 2021-12-30 | Chugai Pharmaceutical Co Ltd | Claudin-6 binding molecules and uses thereof |
-
2021
- 2021-03-30 PE PE2022002151A patent/PE20221760A1/es unknown
- 2021-03-30 CR CR20220540A patent/CR20220540A/es unknown
- 2021-03-30 BR BR112022017305A patent/BR112022017305A2/pt unknown
- 2021-03-30 WO PCT/JP2021/013526 patent/WO2021200939A1/en active Application Filing
- 2021-03-30 CA CA3174094A patent/CA3174094A1/en active Pending
- 2021-03-30 TW TW111120832A patent/TW202235442A/zh unknown
- 2021-03-30 EP EP21778912.2A patent/EP4126956A4/en active Pending
- 2021-03-30 US US17/913,899 patent/US20230220066A1/en active Pending
- 2021-03-30 IL IL296478A patent/IL296478A/en unknown
- 2021-03-30 TW TW110111555A patent/TWI770917B/zh active
- 2021-03-30 CN CN202180025880.6A patent/CN115397855A/zh active Pending
- 2021-03-30 MX MX2022012092A patent/MX2022012092A/es unknown
- 2021-03-30 JP JP2021056457A patent/JP6971419B2/ja active Active
- 2021-03-30 KR KR1020227027058A patent/KR20220149774A/ko not_active Application Discontinuation
- 2021-03-30 SG SG11202104264TA patent/SG11202104264TA/en unknown
- 2021-03-30 AU AU2021247916A patent/AU2021247916A1/en active Pending
- 2021-03-30 KR KR1020217036902A patent/KR102431028B1/ko active IP Right Grant
- 2021-11-01 JP JP2021178682A patent/JP2022009816A/ja active Pending
-
2022
- 2022-09-27 CL CL2022002625A patent/CL2022002625A1/es unknown
- 2022-10-26 CO CONC2022/0015202A patent/CO2022015202A2/es unknown
-
2023
- 2023-07-19 CL CL2023002099A patent/CL2023002099A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3174094A1 (en) | 2021-10-07 |
| TW202204408A (zh) | 2022-02-01 |
| KR20220149774A (ko) | 2022-11-08 |
| TWI770917B (zh) | 2022-07-11 |
| KR20210143923A (ko) | 2021-11-29 |
| CR20220540A (es) | 2022-12-07 |
| IL296478A (en) | 2022-11-01 |
| JP6971419B2 (ja) | 2021-11-24 |
| CO2022015202A2 (es) | 2022-11-18 |
| EP4126956A4 (en) | 2024-04-24 |
| JP2021168648A (ja) | 2021-10-28 |
| WO2021200939A1 (en) | 2021-10-07 |
| US20230220066A1 (en) | 2023-07-13 |
| CN115397855A (zh) | 2022-11-25 |
| CL2022002625A1 (es) | 2023-04-21 |
| JP2022009816A (ja) | 2022-01-14 |
| AU2021247916A1 (en) | 2022-10-20 |
| CL2023002099A1 (es) | 2023-12-22 |
| EP4126956A1 (en) | 2023-02-08 |
| TW202235442A (zh) | 2022-09-16 |
| PE20221760A1 (es) | 2022-11-11 |
| MX2022012092A (es) | 2022-10-13 |
| KR102431028B1 (ko) | 2022-08-10 |
| SG11202104264TA (en) | 2021-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017305A2 (pt) | Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas | |
| CL2021002242A1 (es) | Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) | |
| BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
| CL2023002108A1 (es) | Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso. | |
| EA202092032A1 (ru) | Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения | |
| BR112022014522A2 (pt) | Compostos degradadores, composição farmacêutica, métodos para tratar transtornos, compostos | |
| BR112021005722A2 (pt) | moléculas de ligação ao antígeno capazes de ligar cd3 e cd137, porém não simultaneamente | |
| BR112022004047A2 (pt) | Proteínas de ligação multiespecíficas para o tratamento de câncer | |
| BR112022005026A2 (pt) | Conjugados terapêuticos | |
| BR112019005685A2 (pt) | células t com resistência à imunossupressão aumentada | |
| AR122018A1 (es) | Proteínas que se unen a nkg2d, cd16 y clec12a | |
| BR112021025720A2 (pt) | Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados | |
| BR112022024833A2 (pt) | Conjugados anticorpo anti-bcma-fármaco e métodos de uso | |
| BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
| BR112021019471A2 (pt) | Composições imunoterapêuticas e uso das mesmas | |
| AR120223A1 (es) | Proteínas que unen nkg2d, cd16 y flt3 | |
| BR112022008756A2 (pt) | Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso | |
| BR112022008552A2 (pt) | Moléculas de ligação multiespecíficas de scfv de terminal-n | |
| CL2021000316A1 (es) | Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso | |
| BR112021012667A2 (pt) | Proteínas de ligação anti-pd-1 e métodos de uso destas | |
| BR112019015453A2 (pt) | Agentes ligantes | |
| BR112021019328A2 (pt) | Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados | |
| BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos | |
| BR112018000909A2 (pt) | imunoconjugados de il22 | |
| BR112017016379A2 (pt) | imunoconjugados, composição, uso de peptídeo, uso de imunoconjugado, método de geração de imunoconjugado e método de tratamento de pacientes |